.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a median consequence of 11 months, clients along with metastatic gastrointestinal lumps that obtained biomarker-matched treatments based on circulating lump DNA profiling revealed a better professional advantage than those receiving unparalleled therapy.